Study analysis · The Journal of physiology · 2025
This weight-loss drug shrinks your muscles—just like dieting—but here’s the twist: they grow back faster than you think.
Semaglutide and eating less both make mice lose the same amount of muscle, but semaglutide loses more fat—and all the muscle comes back after stopping.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This study looked at mice that got a medicine and mice that ate less food, and found both lost muscle and fat in similar ways. But it doesn't prove the medicine caused the muscle loss — it just shows they happened together in these mice.
What’s the bottom line?
This study tested a popular weight-loss drug called semaglutide in obese mice and compared it to just eating less food.
How strong is this study?
The scientists did a pretty good job by comparing the medicine to eating less food and measuring lots of things like muscle strength and energy use. But they didn't say if the people doing the measurements knew which mice got the medicine, so there's a small chance they accidentally influenced the results.
35 / 100
- COI disclosureconflicts of interest not disclosed
- Data availability+35/35
- Code availabilitycode not shared
59 / 100
- Randomization+20/20
- Blindingblinding unclear
- Control group+15/15
- Sample size (n=20)+1.9/20
- Follow-up+10/10
100 / 100
54 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 518 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
This design cannot establish causation — the findings describe an association, not a cause. Although randomization was used, blinding was unknown and the study was conducted in mice, not humans. Without confirmed blinding and human data, causation cannot be reliably established. The design is a controlled animal experiment but lacks the full rigor of an RCT for causal inference in humans.
No Conflicts
No conflicts of interest identified
No conflicts of interest or funding statements were disclosed in the provided text; all authors are affiliated with academic institutions with no apparent industry ties.
The study appears to be conducted by academic researchers affiliated with the University of British Columbia and BC Children's Hospital Research Institute. No funding sources, industry affiliations, or conflict of interest disclosures were provided in the text, which limits full assessment but suggests low risk of bias based on available information.
Key takeaways
- 01
Both the drug and eating less caused the same amount of muscle loss and weaker grip strength.
- 02
But the drug made the mice lose more fat and total weight.
- 03
After stopping, all muscle and fat came back to normal.
- 04
Yes — losing muscle while losing weight is a concern because it can weaken movement and metabolism, but this study shows the muscle loss isn't permanent.
Surprising findings
- Semaglutide and calorie restriction reduced muscle strength by the same amount (30–38%), even though semaglutide caused twice the fat loss.Most assume drugs like Ozempic preserve muscle better than dieting—this shows the opposite: muscle loss is tied to calorie deficit, not the drug’s direct effect.
- Muscle mass and strength fully recovered to baseline levels within 6 weeks after stopping treatment.Many fear permanent muscle loss after stopping GLP-1 drugs—this study shows recovery is complete, not partial or delayed.
- Semaglutide upregulated muscle atrophy genes (Fbxo32, Klf15) while calorie restriction did not—even though both caused identical muscle loss.If muscle loss is the same, why does only the drug trigger atrophy genes? This suggests semaglutide may stress muscle differently than diet.
Practical takeaways
If you’re on semaglutide, prioritize resistance training and high-protein meals to help preserve muscle during weight loss.
This study was in mice—human muscle recovery may differ, and protein intake is harder to achieve with appetite suppression.
medium confidenceDon’t panic if you lose muscle on semaglutide—this study shows it fully recovers within 6 weeks after stopping.
Recovery assumes you return to normal eating; if you overeat, fat may rebound faster than muscle.
high confidenceTrack your strength, not just weight—grip strength is a simple proxy for muscle health during weight loss.
Grip strength was measured in mice; humans need more comprehensive assessments like DEXA or bioimpedance.
medium confidenceWhy this study matters
Same Muscle Loss, More Fat Loss
In obese mice, semaglutide caused 19% total body weight loss versus 11% with matched calorie restriction—yet both groups lost identical amounts of muscle mass and grip strength (30–38% reduction). This means semaglutide’s extra fat loss isn’t due to more muscle breakdown.
People think weight-loss drugs like Ozempic magically burn fat without hurting muscle—this study proves muscle loss is just a side effect of calorie deficit, not the drug itself.
Muscle Loss Isn’t Permanent
After 6 weeks of stopping semaglutide or calorie restriction, mice fully regained all lost muscle mass and grip strength, returning to baseline levels—no lingering damage.
This flips the fear that GLP-1 drugs cause permanent muscle damage. Recovery isn’t just possible—it’s complete and rapid.
Different Genes, Same Outcome
Semaglutide upregulated muscle atrophy genes like Fbxo32 (atrogin-1) and Klf15—genes linked to muscle breakdown—while calorie restriction did not, despite identical muscle loss.
Even though both methods shrink muscle, the drug triggers a different molecular signal—suggesting it might be more stressful to muscle tissue than diet alone.
Why Semaglutide Burns More Fat
Despite identical calorie intake, semaglutide-treated mice lost twice as much fat as pair-fed mice—suggesting the drug may reduce nutrient absorption or increase fat excretion, though this wasn’t measured.
If semaglutide makes your body dump fat calories in poop, that’s a game-changer for understanding how it works beyond appetite suppression.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
This study tested a popular weight-loss drug called semaglutide in obese mice and compared it to just eating less food.
Research results
Both the drug and eating less caused the same amount of muscle loss and weaker grip strength. But the drug made the mice lose more fat and total weight. After stopping, all muscle and fat came back to normal.
What this means - more context
Yes — losing muscle while losing weight is a concern because it can weaken movement and metabolism, but this study shows the muscle loss isn't permanent.
This study investigates whether semaglutide causes greater muscle loss than caloric restriction in obese mice, and whether muscle mass recovers after treatment discontinuation.
Semaglutide and matched caloric restriction caused similar reductions in skeletal muscle mass and grip strength in obese mice, despite semaglutide producing greater overall and fat weight loss. Transcriptomic changes differed between groups, with semaglutide upregulating atrophy-related genes. All muscle and fat mass losses were fully reversed within 6 weeks after stopping treatment.
Methods Used
C57BL/6J mice with diet-induced obesity received 4 weeks of daily semaglutide injections or calorie-matched pair-feeding, followed by 6 weeks of withdrawal. Body composition, grip strength, energy expenditure, and muscle transcriptomes were measured. Two experimental cohorts were used.
Main Finding
Semaglutide and caloric restriction reduced muscle mass and strength to the same extent, despite semaglutide causing greater fat and total weight loss. Muscle mass and strength fully recovered to baseline after 6 weeks of treatment discontinuation.
Confidence Level
High
Study Flags
Red Flags
- •Animal model (mice), not humans
- •No measurement of nutrient absorption or fecal energy excretion to explain greater fat loss
- •Muscle transcriptome changes not linked to functional outcomes
Surprising Findings
Semaglutide and calorie restriction reduced muscle strength by the same amount (30–38%), even though semaglutide caused twice the fat loss.
Most assume drugs like Ozempic preserve muscle better than dieting—this shows the opposite: muscle loss is tied to calorie deficit, not the drug’s direct effect.
Practical Takeaways
If you’re on semaglutide, prioritize resistance training and high-protein meals to help preserve muscle during weight loss.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 518 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Animal Cohort Study
Subject
Lower probability
on the GRADE evidence scale
This study looked at mice that got a medicine and mice that ate less food, and found both lost muscle and fat in similar ways. But it doesn't prove the medicine caused the muscle loss — it just shows they happened together in these mice.
No conflicts of interest were detected in this study. No score impact.
Strengths
- Use of a matched caloric restriction control group
- Comprehensive measurement of body composition, muscle mass, and function
- Transcriptomic analysis to explore molecular mechanisms
Weaknesses
- Blinding status unknown, risking performance and detection bias
- Small sample size limits statistical power
- Only male mice studied, limiting generalizability to females
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
This study tested a popular weight-loss drug called semaglutide in obese mice and compared it to just eating less food.
Research results
Both the drug and eating less caused the same amount of muscle loss and weaker grip strength. But the drug made the mice lose more fat and total weight. After stopping, all muscle and fat came back to normal.
What this means - more context
Yes — losing muscle while losing weight is a concern because it can weaken movement and metabolism, but this study shows the muscle loss isn't permanent.
This study investigates whether semaglutide causes greater muscle loss than caloric restriction in obese mice, and whether muscle mass recovers after treatment discontinuation.
Semaglutide and matched caloric restriction caused similar reductions in skeletal muscle mass and grip strength in obese mice, despite semaglutide producing greater overall and fat weight loss. Transcriptomic changes differed between groups, with semaglutide upregulating atrophy-related genes. All muscle and fat mass losses were fully reversed within 6 weeks after stopping treatment.
Methods Used
C57BL/6J mice with diet-induced obesity received 4 weeks of daily semaglutide injections or calorie-matched pair-feeding, followed by 6 weeks of withdrawal. Body composition, grip strength, energy expenditure, and muscle transcriptomes were measured. Two experimental cohorts were used.
Main Finding
Semaglutide and caloric restriction reduced muscle mass and strength to the same extent, despite semaglutide causing greater fat and total weight loss. Muscle mass and strength fully recovered to baseline after 6 weeks of treatment discontinuation.
Confidence Level
High
Study Flags
Red Flags
- •Animal model (mice), not humans
- •No measurement of nutrient absorption or fecal energy excretion to explain greater fat loss
- •Muscle transcriptome changes not linked to functional outcomes
Surprising Findings
Semaglutide and calorie restriction reduced muscle strength by the same amount (30–38%), even though semaglutide caused twice the fat loss.
Most assume drugs like Ozempic preserve muscle better than dieting—this shows the opposite: muscle loss is tied to calorie deficit, not the drug’s direct effect.
Practical Takeaways
If you’re on semaglutide, prioritize resistance training and high-protein meals to help preserve muscle during weight loss.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 518 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Animal Cohort Study
Subject
Lower probability
on the GRADE evidence scale
This study looked at mice that got a medicine and mice that ate less food, and found both lost muscle and fat in similar ways. But it doesn't prove the medicine caused the muscle loss — it just shows they happened together in these mice.
No conflicts of interest were detected in this study. No score impact.
Strengths
- Use of a matched caloric restriction control group
- Comprehensive measurement of body composition, muscle mass, and function
- Transcriptomic analysis to explore molecular mechanisms
Weaknesses
- Blinding status unknown, risking performance and detection bias
- Small sample size limits statistical power
- Only male mice studied, limiting generalizability to females
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
The scientists did a pretty good job by comparing the medicine to eating less food and measuring lots of things like muscle strength and energy use. But they didn't say if the people doing the measurements knew which mice got the medicine, so there's a small chance they accidentally influenced the results.
35 / 100
- COI disclosureconflicts of interest not disclosed
- Data availability+35/35
- Code availabilitycode not shared
59 / 100
- Randomization+20/20
- Blindingblinding unclear
- Control group+15/15
- Sample size (n=20)+1.9/20
- Follow-up+10/10
100 / 100
54 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervalsno confidence intervals
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 518 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
This design cannot establish causation — the findings describe an association, not a cause. Although randomization was used, blinding was unknown and the study was conducted in mice, not humans. Without confirmed blinding and human data, causation cannot be reliably established. The design is a controlled animal experiment but lacks the full rigor of an RCT for causal inference in humans.
No Conflicts
No conflicts of interest identified
No conflicts of interest or funding statements were disclosed in the provided text; all authors are affiliated with academic institutions with no apparent industry ties.
The study appears to be conducted by academic researchers affiliated with the University of British Columbia and BC Children's Hospital Research Institute. No funding sources, industry affiliations, or conflict of interest disclosures were provided in the text, which limits full assessment but suggests low risk of bias based on available information.
Standing
The people behind it
The researchers who wrote the study this analysis is built on.
Authored by
13 researchersIf this is your work, this is how we attribute it on Fit Body Science. Stewart Jeromson is listed as the lead author.